ROC Analysis of Biomarker Combinations in Fragile X Syndrome-Specific Clinical Trials: Evaluating Treatment Efficacy via Exploratory Biomarkers

By J. E. Norris, E. Berry-Kravis, Mark D. Harnett, S. A. Reines, Melody R. Smith, Emma Auger, Abigail H. Outterson, Jeremiah Furman, Mark E. Gurney, Lauren E. Ethridge. 2025

Subfields: Genetics, Psychiatry and Mental health, Statistics and Probability

Citations in the corpus

• A human electrophysiological signature of Fragile X pathophysiology is shared in V1 of Fmr1-/y mice (2026, unknown): “This can be compared to recent work in humans with FXS showing that the peak frequency of alpha oscillations could be increased by BPN14770, a phosphodiesterase (PDE)4D allosteric inhibitor 105 .”